FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百奧賽圖(北京)醫藥科技股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02315 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 2. 股份分類 | 普通股 | 股份 ...

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

Core Viewpoint - The company BaiO Saite-B (02315) has seen a significant stock price increase, with a recent rise of over 10%, attributed to its strong earnings forecast for 2025, projecting a net profit increase of 384.26% to 443.88% year-on-year [1] Group 1: Financial Performance - BaiO Saite-B forecasts a net profit for 2025 between 162 million to 182 million yuan, indicating substantial growth compared to previous years [1] - The company attributes its revenue growth to the ongoing expansion in overseas markets and the recovery of the domestic biopharmaceutical industry [1] Group 2: Operational Efficiency - High technical barriers have allowed the company to maintain elevated gross margins, while lean management initiatives have further enhanced operational efficiency [1] - The rapid improvement in profitability is a result of these operational enhancements [1] Group 3: Strategic Partnerships - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, which are expected to contribute to revenue through milestone payments [1] - Notable partnerships include a global licensing agreement with BeiGene for antibody molecules and an agreement with Merck for the development of antibody-drug conjugates using the RenMice platform [1]

Core Viewpoint - Baosai Technology-B (02315) has seen a significant stock price increase, with a recent rise of over 10%, attributed to strong earnings forecasts and strategic partnerships in the biopharmaceutical sector [1] Group 1: Earnings Forecast - The company has projected a net profit attributable to shareholders for 2025 between 162 million to 182 million yuan, representing a year-on-year increase of 384.26% to 443.88% [1] - The growth is driven by the continuous expansion in overseas markets and a recovery in the domestic biopharmaceutical industry, leading to rapid revenue growth [1] Group 2: Operational Efficiency - High technical barriers have ensured that the company's gross profit margin remains elevated, while lean management initiatives have further enhanced operational efficiency [1] - The company's profitability has improved rapidly as a result of these factors [1] Group 3: Strategic Partnerships - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, which are expected to contribute to revenue through milestone payments [1] - Notable partnerships include a global licensing agreement with BeiGene for antibody molecules and an agreement with Merck for the development of antibody-conjugated LNPs using the RenMice platform [1]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

消息面上，公司昨晚公告业绩预告，预计2025年归属于上市公司股东的净利润为1.62亿-1.82亿元，同比增长384.26%至 443.88%。受益于海外市场的持续拓展，叠加国内生物医药（核心股）行业的复苏回暖，公司营业收入实现高速增长。高壁 垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水平得以快速提高。 1月30日，2025年净利同比预增384.26%-443.88%，刺激百奥赛图AH股齐涨。A股一度大涨超18%至78.75元，创上市新高； H股一度飙升超43%至63港元，股价亦创上市新高。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 ...

格隆汇1月30日｜2025年净利同比预增384.26%-443.88%，刺激百奥赛图AH股齐涨。A股一度大涨超18% 至78.75元，创上市新高；H股一度飙升超43%至63港元，股价亦创上市新高。 消息面上，公司昨晚公 告业绩预告，预计2025年归属于上市公司股东的净利润为1.62亿-1.82亿元，同比增长384.26%至 443.88%。受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增 长。高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水 平得以快速提高。 ...

盈喜后涨超40%，截至发稿，涨40.91%，报62港元，成交额5841万港元。 消息面上，百奥赛图发布2025年度业绩预告，预计全年实现营收约13.69亿元-13.89亿元，较上年同期增加3.89亿元至4.08亿元，同比增幅为39.61%到 41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，较上年同期增加1.29亿元至1.49亿元，同比大幅增长384.26%至443.88%。 公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长；高壁垒的技术优势保障业务毛利维持高位，精益化 管理举措进一步推动运营效率提升，公司盈利水平得以快速提高。 编辑/doris ...

Core Viewpoint - The company Baidu Biotechnology (02315) has announced a positive earnings forecast for the fiscal year 2025, leading to a significant increase in its stock price by nearly 13% following the announcement [1] Financial Performance - The company expects to achieve revenue of approximately 1.369 billion to 1.389 billion yuan, representing an increase of 389 million to 408 million yuan compared to the previous year, with a year-on-year growth rate of 39.61% to 41.65% [1] - The anticipated net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, which is an increase of 129 million to 149 million yuan from the previous year, indicating a substantial year-on-year growth of 384.26% to 443.88% [1] Market Dynamics - The company's revenue growth is attributed to the continuous expansion in overseas markets, coupled with a recovery in the domestic biopharmaceutical industry [1] - The high barriers to entry in technology have helped maintain high gross margins, while lean management initiatives have further enhanced operational efficiency, leading to a rapid increase in profitability [1]

公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增 长；高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水 平得以快速提高。 百奥赛图-B(02315)盈喜后涨近13%，截至发稿，涨8.82%，报47.88港元，成交额2771.5万港元。 消息面上，百奥赛图发布2025年度业绩预告，预计全年实现营收约13.69亿元-13.89亿元，较上年同期增 加3.89亿元至4.08亿元，同比增幅为39.61%到41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，较 上年同期增加1.29亿元至1.49亿元，同比大幅增长384.26%至443.88%。 ...